Valeant Says It Has Fixed All Issues at Bausch & Lomb Tampa Plant

Valeant Pharmaceuticals International Inc. says it has fixed the problems at a Bausch & Lomb manufacturing plant in Tampa that delayed work on a new drug for glaucoma.

Valeant (NYSE: VRX) now hopes to get the drug on the market this year, Joseph Papa, chairman and CEO, said during a conference call with analysts early Tuesday.

The Laval, Quebec-based pharmaceutical firm, which has a significant presence in the Tampa Bay area, has been under fire for months.

Back to news